Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk diseaseSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2018Cited by 208
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, Jodi Prime et al.|Blood|2013Cited by 177